source
- Ipsen to acquire Memo Therapeutics and its kidney infection candidateFrench drugmaker Ipsen announced a new acquisition, agreeing to buy Memo Therapeutics along with its experimental kidney infection drug. This marks Ipsen's second transaction announced within a wee…
- 92Bio revives experimental T cell engager previously handed to Amgen92Bio, a small California biotech, announced it is bringing back an experimental T‑cell engager it originally created before transferring the program to Amgen. The company said the candidate will…